<DOC>
	<DOCNO>NCT01151215</DOCNO>
	<brief_summary>The main purpose study compare progression free survival patient treat AZD8931 give combination anastrozole versus anastrozole alone . The secondary objective investigate safety tolerability AZD8931 give combination anastrozole .</brief_summary>
	<brief_title>Study Anastrozole +/- AZD8931 Postmenopausal Women With Endocrine Therapy Naive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>Patients locally advance metastatic breast cancer . Lesions amenable surgery radiation curative intent Hormone therapynaive Estimated life expectancy 12 week Last dose prior anticancer therapy receive within 14 day ( longer require ) Any eye injury corneal surgery within 3 month prior receive first dose study drug . Currently receive ( unwilling discontinue ) oestrogen replacement therapy . ( last dose &lt; 7 day prior randomisation )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Cancer</keyword>
	<keyword>tumour</keyword>
	<keyword>breast cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>secondary</keyword>
	<keyword>locally advanced</keyword>
</DOC>